We have our own point of view on the people, technologies, and conversations that will shape the future.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
Cancer remains one of the leading causes of death in the U.S. and worldwide.
Attention Digital Health Founders: We are now accepting applications to attend the Digital Health Founder’s Fellowship
Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.
We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.
At Menlo, we believe the pace of innovation in new medicines will continue to accelerate, powered by the combination of advances in biology, advances in information technology, and even the lasting implications of the global pandemic.
Here at Menlo, we are building an investing practice focused on three of the most exciting areas of healthcare: therapeutic platforms, digital health, and transformative technologies.
Congratulations to Bernard Coulie and the team at Pliant Therapeutics on a successful IPO!
How can we take a critical process and make it better? Many successful companies are built from answering this question.
When you rent an apartment, buy a car, pay for education, you know exactly what you are going to pay. Why then, when you go to a doctor or pay for healthcare, do you not know what you will owe?
It’s rare to meet an entrepreneur who demonstrates both an incredible command of their business and such a clear vision of the magnitude of the opportunity.
Today, the Aspen Institute announced its fifth class of Health Innovators Fellows, comprised of 21 healthcare leaders from across the industry with diverse expertise.
Today we announce the closing of Menlo Ventures XIV, a $450 million fund earmarked for early-stage technology investments.
The Menlo team is thrilled to announce we have added a new partner, Greg Yap, to lead investments in the health, medical, and life science technology space.